Apotex Receives FDA Approval for Generic Infuvite Pediatric Injection with 180-Day Exclusivity

Key Takeaways

• FDA approves Apotex’s generic Infuvite Pediatric Injection with 180-day Competitive Generic Therapy exclusivity for single-dose vials
• Approval provides more affordable pediatric vitamin therapy options for hospitals and healthcare providers treating children
• Apotex will lead U.S. commercialization in partnership with Orbicular Pharmaceutical Technologies and Gland Pharma Limited

---

Apotex announced on April 27, 2026, that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for generic Infuvite Pediatric Injection, granting the company 180-day Competitive Generic Therapy (CGT) exclusivity for the single-dose vial formulation.

The Weston, Florida-based pharmaceutical company developed the generic pediatric vitamin injection in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited. Apotex serves as the ANDA sponsor and will handle commercialization throughout the United States.

Market Impact and Patient Access

This approval significantly expands access to pediatric intravenous vitamin therapy by introducing a more cost-effective alternative to the brand-name Infuvite Pediatric. The 180-day CGT exclusivity period provides Apotex with temporary market protection, potentially allowing healthcare systems to reduce medication costs while maintaining quality patient care.

The generic approval complements Apotex’s recent FDA approval for generic Infuvite Adult Injection, creating a comprehensive portfolio of intravenous vitamin products across age groups. This dual approval positions the company as a key supplier in the hospital and clinical nutrition market.

Clinical Significance

Infuvite Pediatric Injection delivers essential vitamins to children who cannot receive adequate nutrition orally, including critically ill patients, those with gastrointestinal disorders, or infants requiring parenteral nutrition support. The availability of generic alternatives helps healthcare facilities manage rising medication costs while ensuring consistent access to these vital therapies.

The CGT exclusivity designation recognizes products that address drug shortages or provide significant clinical benefits, highlighting the importance of reliable pediatric vitamin injection supplies in hospital settings.

Partnership Strategy

Apotex’s collaboration with international partners Orbicular Pharmaceutical Technologies and Gland Pharma demonstrates the company’s strategic approach to complex generic drug development. This partnership model allows Apotex to leverage specialized manufacturing capabilities while maintaining control over U.S. market distribution and regulatory compliance.

---

Frequently Asked Questions

What does this approval mean for pediatric patients?

The approval provides hospitals and healthcare providers with a more affordable generic alternative to brand-name Infuvite Pediatric, potentially improving access to essential intravenous vitamin therapy for children who cannot receive adequate nutrition orally.

When will generic Infuvite Pediatric be available in the U.S.?

While Apotex has received FDA approval, the company has not announced a specific launch date. The 180-day exclusivity period suggests commercial availability should begin soon, with Apotex leading U.S. distribution.

How does the 180-day CGT exclusivity benefit patients?

The Competitive Generic Therapy exclusivity provides Apotex with temporary market protection, encouraging generic drug development for products with limited competition, ultimately leading to more treatment options and potentially lower costs for healthcare systems.